MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage many intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Key demo targets were being To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory targets https://johnw110jvf3.wikievia.com/user